References
- Amod A, Ascott-Evans BH, Berg GI, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes (revised). JEMDSA. 2012; 17(2)(Supplement 1): S1–S95.
- Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006; 60(11): 1454–1470.
- White JR. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use. Clin Diabet. 2008; 26(2): 53–57.
- Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs. 2011; 71(11): 1441–1467.
- Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011; 34 Supplement 2: S276–S278.
- Neumiller JJ. Differential chemistry (structure), mechanism of action and pharmacology of GLP-receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc. 2009; 49 Suppl: S16–S29.
- MIMS, November 2012.
- Scheen AJ. Dipeptidyl peptitase-4 inhibitors (gliptins). Focus on drug-drug interactions. Clin Pharmacokinetics. 2010; 49(9): 573–588.
- Onglyza® package insert.
- Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. PT. 2010; 35(9): 509–513.
- Galvus® package insert.
- Galvus Met® package insert.
- Januvia® package insert.